Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PuraPharm's Total Assets for the quarter that ended in Dec. 2025 was HK$693.8 Mil.
During the past 12 months, PuraPharm's average Total Assets Growth Rate was -3.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -10.40% per year.
During the past 5 years, the average Total Assets Growth Rate was -12.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 0.50% per year.
During the past 12 years, PuraPharm's highest 3-Year average Total Assets Growth Rate was 47.80%. The lowest was -15.00%. And the median was -2.30%.
Total Assets is connected with ROA %. PuraPharm's annualizedROA % for the quarter that ended in Dec. 2025 was -3.91%. Total Assets is also linked to Revenue through Asset Turnover. PuraPharm's Asset Turnover for the quarter that ended in Dec. 2025 was 0.24.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PuraPharm's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
PuraPharm Total Assets Related Terms
PuraPharm Total Assets Historical Data
* Premium members only.
The historical data trend for PuraPharm's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PuraPharm's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PuraPharm (HKSE:01498) has a Total Assets of HK$693.8 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on PuraPharm and its competitors.
Is PuraPharm's Total Assets too high?
PuraPharm's current Total Assets is HK$693.8 Mil. Overall, PuraPharm has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PuraPharm's Total Assets compare to ZTS?
PuraPharm's Total Assets of HK$693.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PuraPharm and its competitors. PuraPharm's current Total Assets is HK$693.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PuraPharm stock overvalued right now?
Based on GuruFocus' analysis, PuraPharm (HKSE:01498) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.51, compared to a current price of HK$0.28 — trading 45.1% below its estimated fair value. The current Total Assets is HK$693.8 Mil. PuraPharm's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PuraPharm (HKSE:01498), the current Total Assets is HK$693.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PuraPharm (HKSE:01498) Overvalued in 2026?
Based on GuruFocus' analysis, PuraPharm stock appears to be undervalued.
The current stock price of HK$0.28 is trading 45.1% below its estimated GF Value™ of HK$0.51.
GuruFocus considers PuraPharm to be Possible Value Trap.
Key valuation signals for HKSE:01498:
Total Assets: HK$693.8 Mil
GF Value™: HK$0.51 vs. price of HK$0.28 (45.1% below fair value)
No single metric tells the full story. See the HKSE:01498 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PuraPharm Corporation Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, production, and sale of concentrated Chinese medicine granules (CCMG) and other Chinese healthcare products. Its operations also include the cultivation and trading of raw Chinese herbs, the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces, and the provision of Chinese medical diagnostic services. The Group's reportable operating segments are: China CCMG, Hong Kong CCMG, Chinese healthcare products, Clinics, and Plantation. Maximum revenue is derived from the Hong Kong CCMG segment. Geographically, the Group generates maximum revenue from Hong Kong, and the rest from the Chinese Mainland and other countries.
23GF Score
Get the complete analysis for HKSE:01498
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01498 has been successfully added to your 
